BioCentury | Oct 31, 2005
Finance

Liquidity preference

Low-cost stock markets with "streamlined" regulatory constraints for small-to-medium sized companies again are all the rage in Europe, with other bourses seeking to emulate the success of London's AIM. But while the re-emergence of lightly...
BioCentury | Apr 18, 2005
Finance

Ebb & Flow

As the sign says, "objects in the rear view mirror are closer than they appear." On the heels of last week's positive Phase III data for Avastin as first-line therapy for metastatic breast cancer, and...
BioCentury | Jun 2, 2003
Finance

Ebb & Flow

Optimists should be cheering the fact that investors continued to bid up biotech during the final week in front of the American Society of Clinical Oncology (ASCO) meeting, which opened in Chicago last Friday, even...
BioCentury | Feb 17, 2003
Finance

The new German indexes

...The Deutsche Börse in Frankfurt last week disclosed the composition of its new TecDAX index, which will...
...blue chip index for the technology sectors, including biotech. Last week's announcement comes as the Deutsche Börse...
BioCentury | Sep 26, 2002
Top Story

Deutsche Boerse dissolving NMarkt

Deutsche Boerse said it will discontinue both the Neuer Markt and SMAX of the Frankfurt Stock Exchange by the end of 2003 in a move to restore investor confidence in small- and medium-sized high tech...
BioCentury | Jan 14, 2002
Finance

Ebb & Flow

'The great tragedy of science - the slaying of a beautiful hypothesis by an ugly fact.' - Biologist Thomas Henry Huxley It was hard to ignore the level of swagger and hubris among company executives at the...
BioCentury | Jul 30, 2001
Finance

Neuer Markt or bust?

Germany's biotech stocks have been trapped in the Neuer Markt meltdown since the end of July last year, with 10 biotech listings tracked by BioCentury falling some 70% in aggregate through last week. The meltdown,...
BioCentury | Jul 3, 2000
Finance

Stifling an equity culture

London & the Continent Stifling an equity culture OXFORD - If the focus of the U.S. equity markets this year has been on the positive effects of the human genome project and the unprecedented fundraising activity,...
BioCentury | May 15, 2000
Finance

Crying in their beer

At first blush, the five U.S. IPOs that have priced in the last three weeks have not lived up to their expectations. The group has raised $273 million, but in doing so has left $203...
BioCentury | Apr 26, 2000
Financial News

Deutsche Borse trades MacroChem

MCHM started trading on the Frankfurt Stock Exchange. BC Staff...
Items per page:
1 - 10 of 16
BioCentury | Oct 31, 2005
Finance

Liquidity preference

Low-cost stock markets with "streamlined" regulatory constraints for small-to-medium sized companies again are all the rage in Europe, with other bourses seeking to emulate the success of London's AIM. But while the re-emergence of lightly...
BioCentury | Apr 18, 2005
Finance

Ebb & Flow

As the sign says, "objects in the rear view mirror are closer than they appear." On the heels of last week's positive Phase III data for Avastin as first-line therapy for metastatic breast cancer, and...
BioCentury | Jun 2, 2003
Finance

Ebb & Flow

Optimists should be cheering the fact that investors continued to bid up biotech during the final week in front of the American Society of Clinical Oncology (ASCO) meeting, which opened in Chicago last Friday, even...
BioCentury | Feb 17, 2003
Finance

The new German indexes

...The Deutsche Börse in Frankfurt last week disclosed the composition of its new TecDAX index, which will...
...blue chip index for the technology sectors, including biotech. Last week's announcement comes as the Deutsche Börse...
BioCentury | Sep 26, 2002
Top Story

Deutsche Boerse dissolving NMarkt

Deutsche Boerse said it will discontinue both the Neuer Markt and SMAX of the Frankfurt Stock Exchange by the end of 2003 in a move to restore investor confidence in small- and medium-sized high tech...
BioCentury | Jan 14, 2002
Finance

Ebb & Flow

'The great tragedy of science - the slaying of a beautiful hypothesis by an ugly fact.' - Biologist Thomas Henry Huxley It was hard to ignore the level of swagger and hubris among company executives at the...
BioCentury | Jul 30, 2001
Finance

Neuer Markt or bust?

Germany's biotech stocks have been trapped in the Neuer Markt meltdown since the end of July last year, with 10 biotech listings tracked by BioCentury falling some 70% in aggregate through last week. The meltdown,...
BioCentury | Jul 3, 2000
Finance

Stifling an equity culture

London & the Continent Stifling an equity culture OXFORD - If the focus of the U.S. equity markets this year has been on the positive effects of the human genome project and the unprecedented fundraising activity,...
BioCentury | May 15, 2000
Finance

Crying in their beer

At first blush, the five U.S. IPOs that have priced in the last three weeks have not lived up to their expectations. The group has raised $273 million, but in doing so has left $203...
BioCentury | Apr 26, 2000
Financial News

Deutsche Borse trades MacroChem

MCHM started trading on the Frankfurt Stock Exchange. BC Staff...
Items per page:
1 - 10 of 16